Fangjun Wu

Fangjun Wu is a seasoned professional in the field of CMC development, currently serving as Sr. Director at Ovid Therapeutics since 2020. Before this role, Fangjun held positions as Associate Director at Ferring Pharmaceuticals, where leadership of a CMC team facilitated the preparation of the CTD for NDA filing and oversight of global CDMOs for product development. Previous experience includes a role as Sr. Manager at Shionogi Inc., contributing to the CTD for the NDA filing of a flu drug, and positions at Purdue Pharma L.P. as Principal Scientist, Merck as Associate Principal Scientist, and Schering-Plough Research Institute as Associate Principal Scientist.